A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

857 participants · First posted May 17, 2017

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

42 participants · First posted Sep 8, 2023

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

70 participants · First posted Feb 16, 2022

Selective BRM inhibitor and degrader therapy(Loxo Oncology at Lilly/Foghorn Therapeutics)

LOXO-260

LOXO-102

LOXO ONCOLOGY, INC.

United States

LILLY FRANCE

United States

LILLY SA

Spain

Eli Lilly Advances LOXO-435 in Phase 1 FORAGER-1 Study for FGFR3-Altered Advanced Cancers

Eli Lilly and Loxo Oncology Advance Phase 3 Trial Testing Pirtobrutinib Combination for Previously Treated CLL/SLL

Eli Lilly Acquires Point Biopharma for $1.4 Billion to Expand Radioligand Therapy Portfolio